Cargando…

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics

Detalles Bibliográficos
Autores principales:	Touzeau, Cyrille, Ryan, Jeremy, Guerriero, Jennifer L., Moreau, Philippe, Chonghaile, Triona Ni, Gouill, Steven Le, Richardson, Paul, Anderson, Kenneth, Amiot, Martine, Letai, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714955/ https://www.ncbi.nlm.nih.gov/pubmed/26174630 http://dx.doi.org/10.1038/leu.2015.184

Ejemplares similares

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
por: Jullien, Maxime, et al.
Publicado: (2020)

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
por: Potter, Danielle S., et al.
Publicado: (2021)

Mitochondrial apoptosis and BH3 mimetics
por: Dai, Haiming, et al.
Publicado: (2016)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
por: Bodet, L, et al.
Publicado: (2010)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017)

The application of BH3 mimetics in myeloid leukemias
por: Parry, Narissa, et al.
Publicado: (2021)

Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
por: Oakes, SR, et al.
Publicado: (2012)

BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
por: Ramesh, Prashanthi, et al.
Publicado: (2020)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

Antagonism of Bcl-X(L) is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells
por: Abed, Mohammed Najim, et al.
Publicado: (2016)

BH3-mimetics: recent developments in cancer therapy
por: Townsend, Paul A., et al.
Publicado: (2021)

Sensitivity of canine hematological cancers to BH3 mimetics
por: Jegatheeson, Selvi, et al.
Publicado: (2022)

Hypericin, a potential new BH3 mimetic
por: Doroshenko, Anastasia, et al.
Publicado: (2022)

Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling
por: Peperzak, Victor, et al.
Publicado: (2017)

BCL2DB: database of BCL-2 family members and BH3-only proteins
por: Rech de Laval, Valentine, et al.
Publicado: (2014)

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2016)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
por: Butterworth, Michael, et al.
Publicado: (2016)

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
por: Le Pen, J, et al.
Publicado: (2016)

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
por: Le Pen, J, et al.
Publicado: (2017)

Mutual Regulation of Bcl-2 Proteins Independent of the BH3 Domain as Shown by the BH3-Lacking Protein Bcl-x(AK)
por: Plötz, Michael, et al.
Publicado: (2012)

The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2015)

Overcoming EMT-driven therapeutic resistance by BH3 mimetics
por: Keitel, Ulrike, et al.
Publicado: (2014)

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds
por: Luo, Ming-Jie, et al.
Publicado: (2020)

Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
por: Montero, Joan, et al.
Publicado: (2022)

Computational modeling of DLBCL predicts response to BH3-mimetics
por: Cloete, Ielyaas, et al.
Publicado: (2023)

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models
por: Olesinski, Elyse A., et al.
Publicado: (2021)

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines
por: Koss, Brian, et al.
Publicado: (2016)

The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation
por: Singh, Amandeep, et al.
Publicado: (2018)

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
por: Tutusaus, Anna, et al.
Publicado: (2018)

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
por: Soderquist, Ryan S., et al.
Publicado: (2018)

LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA
por: Selt, Florian, et al.
Publicado: (2021)

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2018)

Molecular Interactions of Prodiginines with the BH3 Domain of Anti-Apoptotic Bcl-2 Family Members
por: Hosseini, Ali, et al.
Publicado: (2013)

Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
por: Liu, Qian, et al.
Publicado: (2019)

BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy
por: Nougarède, Adrien, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0rftfkdom1p781rqdaba6fumoq